Unasyn
Phase 2Small molecule
Unasyn is one of 21 small molecule programs targeting Cleft Palate. It is currently in Phase 2.
2
Indications
2
Total Trials
0
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
19 competitors in Cleft Palate
#DrugCompanyPhaseTrials
1Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Tylenol
KKenvue Brands
Approved
Chirocaine
PPurdue Pharma LP
Phase 3
Methadone Hydrochloride
NNational Institute of Allergy and Infectious Diseases (NIAID)
Approved
TISSEEL
UUniversity Hospital, Ghent
Approved
Bupivacaine Only
Pacira Pharmaceuticals, IncPhase 3
Marcaine
IInnocoll
Phase 2
Paracetamol
GSKPhase 2
Fentanyl/hydromorphone
DDuke University
Approved
Unasyn
SStanford University
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Unasyn. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- SStanford University